Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.
暂无分享,去创建一个
Marie Davidian | Anastasios A Tsiatis | Min Zhang | M. Davidian | A. Tsiatis | K. Mahaffey | Min Zhang | K. Pieper | Kenneth W Mahaffey | Karen S Pieper
[1] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[2] M. J. van der Laan,et al. Causal Effect Models for Realistic Individualized Treatment and Intention to Treat Rules , 2007, The international journal of biostatistics.
[3] J. Robins,et al. Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.
[4] D. Rubin. INFERENCE AND MISSING DATA , 1975 .
[5] M. Davidian,et al. Covariate adjustment for two‐sample treatment comparisons in randomized clinical trials: A principled yet flexible approach , 2008, Statistics in medicine.
[6] J. Robins,et al. Comparison of dynamic treatment regimes via inverse probability weighting. , 2006, Basic & clinical pharmacology & toxicology.
[7] S. Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-Segment elevation acute coronary syndromes managed with an intended early invasive strategy—primary results of the SYNERGY randomized trial☆ , 2004 .
[8] J. Robins,et al. Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers , 1992 .
[9] Stephen R Cole,et al. Adjusted survival curves with inverse probability weights , 2004, Comput. Methods Programs Biomed..
[10] Ronald C. Kessler,et al. Methodological Issues in AIDS Behavioral Research , 1993, AIDS Prevention and Mental Health.
[11] L. Stefanski,et al. The Calculus of M-Estimation , 2002 .
[12] J. Robins,et al. Estimation and extrapolation of optimal treatment and testing strategies , 2008, Statistics in medicine.
[13] J. Robins,et al. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.
[14] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[15] J. Robins. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .
[16] R. Califf,et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.
[17] J. Robins. Analytic Methods for Estimating HIV-Treatment and Cofactor Effects , 2002 .
[18] V. Hasselblad,et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. , 2004, JAMA.
[19] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[20] J. Robins,et al. Estimation of Regression Coefficients When Some Regressors are not Always Observed , 1994 .